XML 41 R29.htm IDEA: XBRL DOCUMENT

Subsequent Events Subsequent Events	6 Months Ended
Subsequent Events Subsequent Events	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS On August 2, 2019, we were informed by the pharmaceutical company, who is a party to a clinical trial collaboration agreement acquired through the Perosphere transaction, of its intention to terminate the agreement. Although we do not believe this company has grounds for termination, the potential termination of the collaboration agreement does not change our overall clinical development plan or timing for ciraparantag. See the Perosphere section of Note Q, “Acquisitions, Collaboration, License and Other Strategic Agreements” for additional detail on this agreement. Based on mutual agreement, on August 6, 2019, we and Prasco terminated the Prasco Agreement based on our determination that it was not commercially viable to continue the relationship and, therefore, we do not expect to ship any further authorized generic product to Prasco. See Note Q, “Acquisitions, Collaboration, License and Other Strategic Agreements.” for additional detail on the Prasco Agreement.